PFE250117P29500
- 3.08
- 0.000.00%
Pfizer Newsroom
Trump's policies remain shrouded in ambiguity. Can the USA biopharmaceutical industry turn the tide by 2025?
After facing a decline in investor returns last year, the biopharmaceutical industry hopes to reverse the downturn by 2025, but remains cautious about the policy focus of the incoming president, Donald Trump.
Express News | FDA : Manufacture of Pfizer's Docetaxel, Injection, 10 Mg/1 Ml (Ndc 0409-1732-01), (Ndc 0409-7870-01) Discontinued - Website
Zai Lab to Seek China Approval for Cervical Cancer Therapy After Positive Trial Data
Market Chatter: Pfizer Appeals Ruling on $75.2 Million Insider Trading Settlement
Pfizer Further Pares Stake in Sensodyne Toothpaste Maker Haleon With £2.5b Sale
Express News | Blocktrade-Haleon Secondary Offering Trade Date 15 Jan; Settlement Date 17 Jan, Bookrunner Says
Express News | Pfizer Has Raised Gross Sale Proceeds of About £2.50 Bln - Bookrunner
Express News | Pfizer Has Sold 700 Mln Ordinary Shares in Haleon at a Price of 357 Pence per Ordinary Share - Bookrunner
Pfizer to Sell 7.7% Stake in Haleon via Secondary Offering
Express News | Pfizer plans to further reduce its shareholding in Helion by approximately 7.7%.
Pfizer further reduced its shareholding in Haleon, cashing out 2.6 billion British Pound.
On January 15, at Glonghui, Pfizer, a USA pharmaceutical company, is again selling shares of the United Kingdom consumer health company Haleon, with estimated cash proceeds of 2.6 billion British Pound. According to the announcement, Pfizer will place 7.7% of Haleon's shares through agents on the London Exchange. Based on Haleon's closing price on Tuesday and the sales documents, the transaction value is expected to be 2.6 billion British Pound. Sources indicate that investors have shown strong interest in Haleon's placement, with subscription amounts exceeding the placement size. Last year, Pfizer also placed Haleon shares, cashing out 2.4 billion British Pound.
Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
Bernstein Reaffirms Their Hold Rating on Pfizer (PFE)
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
Pfizer Options Spot-On: On January 14th, 107.11K Contracts Were Traded, With 3.24 Million Open Interest
On January 14th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 107.11K options for the day, of which put options accounted for 34.75% of the total transactions, and
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
Sector Update: Health Care Stocks Fall Tuesday Afternoon
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
10 Health Care Stocks With Whale Alerts In Today's Session
Pfizer to Cut Haleon Stake